AstraZeneca announced that Brilinta (ticagrelor) met the primary endpoint in the PEGASUS-TIMI 54 study.

PEGASUS-TIMI 54 (PrEvention with TicaGrelor of SecondAry Thrombotic Events in High-RiSk Patients with Prior AcUte Coronary Syndrome – Thrombolysis In Myocardial Infarction Study Group) studied Brilinta 60mg twice daily or 90mg twice daily with low-dose aspirin in over 21,000 patients aged ≥50 years with a history of heart attack and one additional cardiovascular (CV) risk factor for the secondary prevention of atherothrombotic events.

RELATED: Development of Brilinta Reversal Agent Initiated by AstraZeneca

The primary efficacy endpoint was a composite of CV death, myocardial infarction (MI) or stroke. Both doses of Brilinta showed f statistically significant reduction in major cardiovascular thrombotic events in patients with a history of MI. Full study results will be submitted to a scientific meeting in 2015.

Brilinta is a direct-acting P2Y12 receptor antagonist that works by inhibiting platelet activation. Brilinta is currently approved to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina or non-ST-elevation MI or ST-elevation MI).

For more information call (800) 236-9933 or visit